Dermata Therapeutics, Inc. (DRMA)

Over the past six months, Dermata Therapeutics' stock has been impacted by several key events. In May 2025, the company provided a corporate update, reported financial results, and announced the initiation of drug manufacturing for the XYNGARI Phase 3 STAR-2 trial. In July 2025, Dermata received an Australian patent for topical botulinum toxin treatment for hyperhidrosis and announced a 1-for-10 reverse stock split. In August 2025, Dermata Therapeutics provided a corporate update and reported financial results. In September 2025, a strategic pivot was announced to prioritize OTC skin care treatments. In October 2025, Dermata announced the acceptance of a patent application for its next-generation acne treatment by the Australian Patent Office. In November 2025, the company provided a corporate update and reported financial results. The stock experienced a significant decline over the past year.

Specific data regarding the demand seasonality for Dermata Therapeutics, Inc.'s products and services is not publicly available. The dermatology market, in general, can experience some seasonality, with certain conditions or aesthetic procedures potentially seeing fluctuations in demand throughout the year. As Dermata's products target conditions like acne and psoriasis, which can be influenced by environmental factors, there might be underlying seasonal patterns in the broader market for such treatments.

Dermata Therapeutics, Inc. is a late-stage medical dermatology company focused on developing and commercializing pharmaceutical product candidates for treating medical skin diseases and aesthetic applications. Their lead product candidate, XYNGARI, is in Phase 3 clinical studies for acne and has completed Phase 1b trials for psoriasis. The company is also developing DMT410, which has completed Phase 1b trials for hyperhidrosis and aesthetic skin conditions. Dermata's Spongilla technology is incorporated into both XYNGARI and DMT410. In September 2025, Dermata decided to prioritize OTC pharmaceutical dermatology products, planning to launch a once-weekly acne kit in mid-2026.

Dermata Therapeutics, Inc. is headquartered in San Diego, California, United States. Its primary operational and developmental activities are based in the U.S., with clinical trials and patent applications extending to other regions, such as Australia.

Dermata Therapeutics' brand reputation is primarily assessed within the scientific, medical, and investment communities. The available information focuses on clinical trial results, patent approvals, strategic corporate decisions, and financial performance. There is no readily available public information detailing consumer-facing brand reputation.

Major institutional shareholders include Armistice Capital, Llc, UBS Group AG, Tower Research Capital LLC (TRC), SBI Securities Co., Ltd., and Bank Of America Corp /de/. Insider sentiment for Dermata Therapeutics has been positive, with insiders buying shares over the last year.